| Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial JW Murrough, DV Iosifescu, LC Chang, RK Al Jurdi, CE Green, AM Perez, ... American Journal of Psychiatry 170 (10), 1134-1142, 2013 | 1287 | 2013 |
| Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment‐resistant depression RB Price, DV Iosifescu, JW Murrough, LC Chang, RK Al Jurdi, SZ Iqbal, ... Depression and anxiety 31 (4), 335-343, 2014 | 370 | 2014 |
| Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression CN Haile, JW Murrough, DV Iosifescu, LC Chang, RK Al Jurdi, A Foulkes, ... International Journal of Neuropsychopharmacology 17 (2), 331-336, 2014 | 258 | 2014 |
| Ketamine safety and tolerability in clinical trials for treatment-resistant depression LB Wan, CF Levitch, AM Perez, JW Brallier, DV Iosifescu, LC Chang, ... The Journal of clinical psychiatry 76 (3), 10121, 2014 | 237 | 2014 |
| Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial JW Murrough, KE Burdick, CF Levitch, AM Perez, JW Brallier, LC Chang, ... Neuropsychopharmacology 40 (5), 1084-1090, 2015 | 142 | 2015 |
| Legal and ethical implications of CRISPR applications in psychiatry AL Foulkes, T Soda, M Farrell, P Giusti-Rodríguez, G Lázaro-Muñoz North Carolina law review 97 (5), 1359, 2019 | 24 | 2019 |
| Preventing undue discrimination based on psychiatric risk biomarkers C Brennan, G Foulkes, A., Lazaro-Munoz Am J Med Genet Part B, 1-13, 2018 | 16* | 2018 |
| Genetic duties JL Roberts, AL Foulkes William and Mary law review 62 (1), 143, 2020 | 15 | 2020 |
| The impact of brain‐derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy MK Sidhu, PJ Thompson, B Wandschneider, A Foulkes, J De Tisi, ... CNS Neuroscience & Therapeutics 25 (2), 223-232, 2019 | 13 | 2019 |
| Can clinical genetics laboratories be sued for medical malpractice? AL Foulkes, JL Roberts, PS Appelbaum, WK Chung, EW Clayton, B Evans, ... Annals of health law and life sciences 29 (1), 153, 2020 | 3 | 2020 |
| Liberty's Limits & Editing Humanity AL Foulkes NCL Rev. Addendum 98, 1549, 2019 | 1 | 2019 |
| Effects of Intravenous Ketamine on Explicit and Implicit Suicdal Cognition: A Randomized Controlled Trial in Treatment-Resistant Depression R Price, DV Iosifescu, JW Murrough, LC Chang, RK Al Jurdi, DS Charney, ... BIOLOGICAL PSYCHIATRY 73 (9), 142S-143S, 2013 | 1 | 2013 |
| Genetic Villains AL Foulkes SCL Rev. 73, 1, 2021 | | 2021 |
| The Evolutionary Tradition in Law & Metaphor's Double-Edged Sword AL Foulkes Hous. L. Rev. 56, 223, 2018 | | 2018 |
| Clinical Moderators of Antidepressant Response to Ketamine: A Bayesian Analysis AL Foulkes, CE Green, JW Murrough, LC Chang, RK Al Jurdi, ... BIOLOGICAL PSYCHIATRY 75 (9), 126S-126S, 2014 | | 2014 |
| Ketamine for treatment-resistant depression: Subjective effects and impact on plasma brain-derived neurotrophic factor CN Haile, JJ Murrough, DV Iosifescu, LC Chang, RK Al Jurdi, A Foulkes, ... Drug and Alcohol Dependence, e77, 2014 | | 2014 |
| DOES THE BDNF VAL66MET POLYMORPHISM INFLUENCE COGNITIVE FUNCTION IN PATIENTS WITH MTLE? J Stretton, A Foulkes, PJ Thompson, S Baxendale, MK Sidhu, E Williams, ... EPILEPSIA 53, 39-39, 2012 | | 2012 |
